API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
EC5026 is a small molecule drug that is a potent and highly selective inhibitor of the sEH enzyme. It is being evaluated in phase 1 clinical trials for the treatment of acute and chronic pain.
Lead Product(s): EC5026
Therapeutic Area: Neurology Product Name: EC5026
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
No drug-related adverse events or changes in vital signs or clinical labs were observed, and the final clinical study report concludes that EC5026 is safe and well tolerated when given as a single oral dose ranging from 0.5 to 24 mg.
Lead Product(s): EC5026
Therapeutic Area: Neurology Product Name: EC5026
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
EC5026 is the first soluble epoxide hydrolase inhibitor developed to treat neuropathic pain.
Lead Product(s): EC5026
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020